Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health (NYSE:BHC) has appointed Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective July 14, 2025. Lee brings over two decades of experience in financial transformation, mergers and acquisitions, and operational execution.
Prior to joining Bausch Health, Lee served as Vice President and CFO of the Industrial and Energy Division and North America Division at BrandSafway, where he also held the position of Chief Accounting Officer. His previous experience includes leadership roles at Mohawk Industries as VP, Corporate Controller, and Chief Accounting Officer.
Bausch Health Canada (NYSE:BHC) announced that its acne treatment CABTREO is now available through public drug plans in Ontario and Nova Scotia, as well as federal programs NIHB and CSC. CABTREO is a first-of-its-kind triple-combination topical treatment for acne vulgaris in patients 12 years and older.
The prescription gel combines three mechanisms of action: an antibiotic (clindamycin phosphate), a retinoid (adapalene), and an antibacterial agent (benzoyl peroxide). The treatment is administered once daily to affected skin areas and has already been available through most private drug insurance plans.
Bausch Health (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals, have launched a new direct-to-consumer campaign called "I Wish I Knew" for their FDA-approved drug Xifaxan® (rifaximin). The campaign aims to educate about overt hepatic encephalopathy (OHE), a serious complication affecting cirrhosis patients.
The initiative features a 60-second spot highlighting a patient's journey with OHE and treatment with Xifaxan, alongside three new patient testimonials. The campaign emphasizes that up to 80% of cirrhosis patients may develop some form of hepatic encephalopathy, which can cause alterations in consciousness, cognition, and behavior.
The company is collaborating with patient advocacy organizations including Global Liver Institute and American Liver Foundation to raise awareness about chronic liver disease progression and OHE management.
Bausch Health (NYSE:BHC) has scheduled its second quarter 2025 financial results announcement for July 30, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. EDT to discuss the results and provide a business update.
The presentation materials will be available on the company's Investor Relations website before the call, and a replay will be accessible afterward at ir.bauschhealth.com/events-and-presentations.
Bausch Health Companies (NYSE/TSX: BHC) held its 2025 Annual Meeting of Shareholders on May 13, 2025, where shareholders elected all 10 nominated directors to the board. The meeting saw significant participation with vote counts ranging from approximately 199-208 million votes in favor for different directors. Notable directors elected include Thomas J. Appio, Brett M. Icahn, and John A. Paulson.
Additionally, shareholders approved three key items: a non-binding advisory vote on executive compensation, the 2025 Employee Stock Purchase Plan (ESPP), and the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm through the 2026 annual meeting.
Bausch Health Companies announced new data showing that patients hospitalized for overt hepatic encephalopathy (OHE) had a reduced risk of 30-day rehospitalization when treated with Xifaxan® (rifaximin) after discharge, regardless of prior treatment. The claims-based analysis of 7,880 OHE patients revealed that those receiving only lactulose upon discharge had a higher risk of 30-day OHE rehospitalization compared to Xifaxan recipients (adjusted OR: 1.63-2.73, p0.05).Prior to hospitalization, 27.1% of patients were treated with Xifaxan, 24.1% with lactulose, and 48.8% received no treatment. The findings support AASLD treatment guidelines recommending Xifaxan as an add-on to lactulose after breakthrough OHE episodes to prevent recurrence. Up to 80% of cirrhosis patients eventually develop some form of HE.
Bausch Health reported strong Q1 2025 financial results with consolidated revenues of $2.26 billion, marking a 5% increase year-over-year. The company achieved its eighth consecutive quarter of growth, with a 6% revenue increase and 14% Adjusted EBITDA growth for Bausch Health excluding Bausch + Lomb.
Key highlights include:
- Salix segment grew 9% to $542 million
- Solta Medical segment surged 28% to $113 million
- Bausch + Lomb segment increased 3% to $1.14 billion
Despite posting a GAAP net loss of $58 million, the company successfully completed a $7.9B refinancing in April to extend maturities. Bausch Health maintained its full-year 2025 Revenue and Adjusted EBITDA guidance while updating its Adjusted Cash Flow from Operations guidance to reflect higher interest expenses.
Bausch Health and its aesthetic business Solta Medical have received Health Canada clearance for their Thermage FLX system, an advanced non-invasive radiofrequency skin tightening technology.
The fourth-generation Thermage FLX system offers several key improvements:
- 25% faster treatments with a larger 4.0 cm² treatment tip
- Enhanced patient comfort through integrated vibration and cooling
- Smart AccuREP technology that adjusts RF energy based on skin impedance
- Ergonomic handpiece design for improved provider workflow
- Versatile applications for face, eyes, and body treatments
This approval marks a significant milestone for Bausch Health's aesthetic business growth in Canada, bringing the same advanced technology already used in leading aesthetic clinics worldwide to Canadian providers and patients. The system builds on Thermage's 20-year legacy of trusted non-invasive skin tightening solutions.
Bausch Health (NYSE:BHC) has announced the launch of Fraxel FTX™, the next generation of skin resurfacing technology, at the ASLMS 2025 Conference in Orlando. The product will be initially rolled out to US dermatologists and aesthetic professionals, with global expansion planned in coming months.
The new Fraxel FTX™ features dual wavelength fractional laser technology (1550nm and 1927nm), targeting both superficial and deeper skin layers. Key improvements include:
- 20% reduction in handpiece weight and size with integrated cooling
- Intelligent Optical Tracking® with AccuTRAC™ for efficient treatment delivery
- Redesigned console with integrated arm
- New color touch screen interface for personalized treatments
The device is indicated for various dermatological procedures including skin resurfacing, treatment of dyschromia, actinic keratosis, melasma, wrinkles, and scars.
Bausch Health (NYSE:BHC) has filed a supplement to its April 2, 2025 proxy statement, revealing that Carl Icahn and affiliates have acquired cash-settled equity swaps for approximately 90.7 million common shares (24.6%), in addition to their 34.7 million beneficially owned shares (9.4%). This brings Icahn's total economic interest to approximately 34% of outstanding shares.
The company's Board directed a review of Icahn's swap positions and John Paulson's bond holdings. Icahn's swaps were accumulated between May 2021 and September 2023, with a February 2028 maturity date. Paulson, the Board Chairman, holds $50 million in Bausch Health bonds and plans to dispose of these securities to avoid potential conflicts of interest.
In response, Bausch Health implemented a shareholder rights plan (SRP) on April 14, 2025, designed to prevent any entity from acquiring 20% or more of outstanding shares without complying with permitted exemptions.